REG - Allergy Therapeutics - Commencement of Phase III Paediatric Trial

Allergy TherapeuticsAnnouncement

21/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241021:nRSU8311Ia&default-theme=true

RNS Number : 8311I  Allergy Therapeutics PLC  21 October 2024

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")

 

Allergy Therapeutics commences Phase III paediatric trial for Grass MATA MPL

 

·      Industry first long-term subcutaneous allergen-specific
immunotherapy (SCIT) trial for grass pollen in paediatric subjects

·      Patient screening and enrolment underway with topline safety and
efficacy data expected Q4 2025

 

21 October 2024 Allergy Therapeutics (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, today
announces that the first subjects have been screened and enrolled in the
Group's Phase III G308 trial to evaluate the long-term efficacy and safety of
Grass MATA MPL in paediatric subjects.

 

Grass MATA MPL is the Group's short-course subcutaneous allergen-specific
immunotherapy (SCIT) candidate that aims to address the cause of symptoms of
allergic rhinoconjunctivitis due to grass pollen.

Incorporating MicroCrystalline Tyrosine ("MCT(®)") adsorbed allergoids and
the innovative adjuvant Monophosphoryl-lipid A ("MPL"), the immunotherapy
candidate has been developed to modify the allergic response following only
six injections prior to the grass allergy season.

 

Commencement of the G308 paediatric trial follows the successful earlier
completion
(https://www.londonstockexchange.com/news-article/AGY/g306-grass-phase-iii-trial-meets-primary-endpoint/16207998)
of the Group's pivotal Phase III G306 trial in adults. In that trial, Grass
MATA MPL demonstrated a highly statistically significant reduction
in the Combined Symptom & Medication Score (CSMS) compared to placebo
over the peak pollen season. Building on these positive results, G308 is
designed to evaluate the long-term efficacy and safety of the immunotherapy
candidate in a paediatric population over five years. Topline safety and
efficacy data are expected in Q4 2025.

 

The G308 paediatric trial complements Allergy Therapeutics' previous studies
in adults, including the pivotal Phase III G306 trial and the exploratory G309
field study, furthering the Group's comprehensive development strategy for
Grass MATA MPL across different age groups.

 

Manuel Llobet, CEO of Allergy Therapeutics, commented: "The commencement of
our long-term paediatric Phase III trial (G308) marks the first time a SCIT
grass pollen vaccine has been evaluated in a paediatric population over the
long-term, a significant milestone in the allergy industry. Encouraged by the
results of our short-course grass pollen immunotherapy in both the successful
G309 exploratory field trial and the pivotal G306 trial, we are excited to
advance the development of this innovative treatment candidate in new patient
populations, potentially offering a transformative option for children with
grass pollen allergies."

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy
product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

 

Grass MATA MPL contains an extract of 13 grass pollens modified with
glutaraldehyde to form allergoids that reduces the reactivity with
immunoglobulin E (IgE) antibodies without a reduction in other important
immunological properties, such as T-cell reactivity. The allergoid is adsorbed
to microcrystalline tyrosine as a depot adjuvant system formulation.
Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the
immunogenic effect of the immunotherapy and to enhance the switch from an
allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1)
like immune response.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESQKFBPQBDDAKD